Improving early detection, diagnosis, treatment monitoring and prognosis of cancer will require rapid and high throughput detection, identi®cation, and measurement of multiple biomarkers. In this study, we demonstrate the versatility of the innovative SELDI ProteinChip 1 MS technology for the rapid, reproducible and simultaneous identi®cation of four well-characterized prostate cancer-associated (PCA) biomarkers, prostate speci®c antigen (free and complexed forms), prostate speci®c peptide, prostate acid phophatase and prostate speci®c membrane antigen in cell lysates, serum and seminal plasma. Proteins corresponding to the mass of these biomarkers could readily be captured and detected using either chemically de®ned or antibody coated ProteinChip 1 arrays. Several (yet to be identi®ed) proteins were found upregulated in cell lysates of pure populations of PCA cells procured by laser capture microdissection (LCM) when compared with mass spectra of normal cell lysates. Coupling LCM with SELDI provides tremendous opportunities to discover and identify the signature proteins associated with each stage of tumor development. Collectively, these observations demonstrate the potential of SELDI for the discovery and simultaneous detection of and clinical assay development for PCA biomarkers in complex biological mixtures.
Introduction
The search for proteins associated with disease is a major challenge. Often discovery of what appears to be unique protein biomarkers fails to be effective when attempts are made to translate them to the clinical setting. Furthermore, increasing evidence suggests that no single biomar-ker will be effective in improving detection, diagnosis, and prognosis. Identifying cancer biomarkers illustrates the problem. Although several biomarkers have been identi®ed and put into clinical practice, for example carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP), neither is effective for early detection of cancer. They are best used for monitoring the effectiveness of the patient's treatment. 1 ± 3 Prostate speci®c antigen (PSA), considered to be the best cancer marker presently available, does not always correctly differentiate benign from malignant prostate disease, and can miss some signi®cant prostate cancers. 4, 5 Based on these limitations, considerable effort has been made to`improve' the PSA test by measuring the free and complex forms of PSA in addition to the total PSA. 5, 6 Although the various versions of these modi®ed PSA tests have reduced the false positive rate, there are still patients with benign and malignant prostate disease that are misidenti®ed. 5, 6 These illustrations clearly suggest that better biomarkers need to be identi®ed and support the likelihood that multiple biomarkers will be required to enhance and improve early detection, diagnosis and prognosis. The tremendous cellular heterogeneity of most human cancers supports this tenant. As an example, germ-cell tumors of the testes can develop from either the embryonic yolk sac, or trophoblastic or both cell types. It is, therefore, critical to measure serum levels of both AFP (yolk sac) and beta HCG (trophoblastic cells) in monitoring these patients following therapy to detect persistent disease. 2, 3 The classical approach for discovering disease-associated proteins continues to be two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Although 2D-PAGE is unchallenged in its ability to resolve thousands of proteins, it is labor intensive, requires large quantities of protein, lacks critical reproducibility standards from one laboratory to another, and is not easily converted into a diagnostic test. Recent advances in desorption mass spectrometry (MS) are beginning to offer an alternative to or an interface with two dimensional electrophoresis for the simultaneous detection and identi®cation of multiple protein species. The most dramatic change occurred with the introduction of an organic matrix to transfer energy to the analyte coupled with a time of¯ight instrument to detect the ionized analytes. This MS version, known as matrix-assisted laser desorption/ionization ± time of ight (MALDI-TOF) MS, has become a tool of choice in recent years for protein analyses, with applications ranging from protein sequence analysis, structure, purity, heterogeneity and cleavage, to postranslational modi®ca-tion, and a host of other molecular characteristics that are often dif®cult to study by other means. 7 Some limitations in MALDI, such as the extensive and exacting sample preparation required, cocrystallization of sample with matrix, the presence of matrix-adduct formation, and background problems resulting from inorganic and organic contaminants, have made it dif®cult to reproducibly detect and identify proteins in complex mixtures. The development of surface enhanced laser desorption/ ionization (SELDI) 8 ± 11 TOF-MS, has largely overcome many of the limitations of MALDI. Based on these initial studies, Ciphergen Biosystems Inc. has introduced the ProteinChip 1 SELDI mass spectrometry technology. This novel technology essentially reverses the conventional MALDI sample preparation scheme by using a ProteinChip 1 array of addressable protein binding sites on a solid substrate. The binding sites are generally chemical or biochemical af®nity ligands, but could conceivably be any desired method to capture any molecule of choice. The chip is incubated with sample, such as complex mixture or pure protein preparations, and residual material (ie buffers, salts, detergents, organics, other proteins, etc) that might interfere with conventional MALDI-TOF, is removed by washing steps. Most importantly the ProteinChip 1 system can analyze trace amounts (ie femtomole or attomole) of native proteins in their natural state, because the`wash and read' process increases thè signal-to-noise' ratio, and capture speci®city is in¯u-enced by wash stringency. By combining an array of different surfaces and wash conditions in a`combinatorial' fashion, high speed, high resolution chromatographic separations are achieved`on-chip'. Finally, a molecule that absorbs laser energy (energy absorbing molecule or EAM), the SELDI equivalent of the MALDI matrix, is added to the chip array and the chip array subjected tò on-chip' laser desorption mass analysis to provide a molecular weight-based protein pro®le.
The ProteinChip 1 SELDI appears to be a highly versatile analytical MS system with considerable potential for the detection, identi®cation and quantitation of proteins in complex mixtures. The purpose of this study was to determine the effectiveness of the SELDI system for simultaneously detecting four well-characterized prostate cancer-associated (PCA) protein biomarkers (PSA, prostate acid phosphatase (PAP), prostate speci®c peptide (PSP), and prostate speci®c membrane antigen (PSMA)), 12 ± 14 and its potential for discovery of unique PCA protein biomarkers in lysates of microdissected cells, and in body¯uids. We successfully demonstrate the direct capture and detection of the four known PCA biomarkers on both chemical and biologically de®ned chip surfaces, and show the potential of SELDI for the rapid discovery of new prostate cancer-associated biomarkers.
Materials and methods
Tissue, serum and semen specimens Tissue, serum and semen specimens were obtained from the Virginia Prostate Center tissue and body¯uid bank. Prostate tissue specimens were procured at the time of surgery, immediately frozen in liquid nitrogen, and stored at 780 C. Serum specimens were obtained as part of a prostate-screening program or as part of routine patient examinations and stored at 780 C. Semen was collected from patients seen in the Department of Urology after informed consent. The semen samples were processed as previously described and stored at 780 C. 14 
Pure proteins (antigens)
Eastern Virginia Medical School-Prostate Speci®c Antigen (EVMS-PSA) and Eastern Virginia Medical SchoolProstatic Acid Phosphatase (EVMS-PAP) were puri®ed from human semen following the procedure described by Wang et al. 15 Puri®ed PSA was also purchased from three commercial sources: Biodesign International (Kennebunk, Maine), Medix Biotech Inc. (Foster City, CA), and Sigma (St Louis, MO). All four of these preparations contained 95 ± 98% pure the free form of PSA. Complexed PSA (95% pure PSA/alpha ± 1-antichymotrypsin complex; PSA-ACT), was purchased from Biodesign International. PSP94 was a gift from Dr James Xuan (University of Western Ontario). A fully glycosylated recombinant PSMA (rPSMA) was prepared using the baculovirus/ insect system following published standard protocols.
Antibodies
Monoclonal antibodies (MoAb) to PSA (clone 5; IgG1) and PSP (clone 19; IgG1) were produced in our laboratory. 16 The Cell lysates A total of 2000 ± 3000 microdissected cells were lysed in 5 ± 10 ml of 5 M guanidinium isothiocyanate in buffer, or 20 mM Hepes with 0.1% Triton X-100. The entire lysate was then spotted on a SAX2 (Strong Anionic Exchanger: quaternary ammonium) or H4 ProteinChip 1 array. Mass analysis was performed in the SELDI PBS I using a-cyano-4-hydroxy cinnamic acid for the SAX surface and sinapinic acid for the H4 surface.
Serum and seminal plasma Serum samples were diluted (20 ml in 30 ml 8 M urea, 1% CHAPS, in PBS) and depleted of albumin by using a cibracon blue spin column. Seminal plasma (SP) samples were diluted (20 ml SP with 30 ml of a buffer containing 9.5 M urea, 2% CHAPS, 50 mM Tris pH 9.5) followed by a further dilution in 1:9 in 50 mM HEPES.
For each sample type, 5 ml was spotted onto SAX, Cu-IMAC or Mixed Mode (anionic and hydrophobic surfaces) ProteinChip 1 arrays, and mass analysis performed using sinapinic acid as the matrix.
SELDI immunoassays
Single antibody assays Protein G (Sigma) at 0.5 mg/ml in 50 mM sodium bicarbonate pH 8.0 was added to the spots of a pre-activated ProteinChip 1 array (PSI) (Ciphergen Biosystems Inc., Palo Alto, CA). The PS1 chip array employed consisted of a carbonyldiimidazole surface that docks proteins by covalently reacting with their amine groups. The chips were incubated for 2 h at room temperature with shaking. After blocking residual active sites with 20 ml 1M ethanolamine, the chip was washed in a 15 ml conical tube with 1% Triton X-100 in PBS followed by 0.1 M sodium acetate, 0.5 M NaCl, pH 4.5 and then 0.1 M Tris ± HCl, 0.5 M NaCl, pH 8.0. The ®nal wash was with PBS (pH 7.4) twice. Anti-PSA, mouse IgG1 (0.25 mg/ ml), anti-PSMA (0.5 mg/ml) or anti-PSP (0.25 mg/ml) was added to individual spots (1 ml) and incubated in a humid chamber for 2 h with mixing. The unbound antibodies were removed by washing the chips with 0.1% Triton-X-100 in PBS twice followed by PBS three times in bulk. Standard curves were generated for each antigen by adding 1 ml of varying protein concentrations of puri®ed antigen to individual spots. For the immunoassay of control and patient serum or seminal plasma, a bioprocessor that ®ts over the ProteinChip 1 array much like a dot-blot apparatus was employed to increase the volume that could be added to each spot. With the bioprocessor clamped onto the chip, the chip was conditioned by washing with 200 ml of 0.5% Triton X-100 in PBS. The serum and SP samples were diluted 1:1 with 0.5% Triton X-100 in PBS, 200 ± 400 ml added to each chip array, and the chips incubated at 4 C overnight with mixing. The spots were washed with 0.5% Triton X-100 in PBS followed by 1 M urea in PBS, and the chip rinsed in HPLC water twice. Sinapinic acid was added, and mass analysis performed with a combination of 140 laser shots throughout each spot. Data for the immunoassays was plotted using log peak area of the antigen of interest.
Multiplex immunoassays For the multiplex immunoassay the same procedure was performed as above, except that two antibodies were simultaneously added to chip arrays in a total of 2 ml. The concentration of the antibodies was doubled to make up for any dilution effect. SP was used as the antigen source with a 1:1 dilution in 0.5% Triton X in PBS.
Results
Puri®ed protein biomarkers SELDI analysis of pure protein biomarkers bound to chemically de®ned protein chips is shown in Figure 1 . Mass spectra of PSP bound to a hydrophobic H4 chip showed three peaks at 10740.3, 10951.8 and 11161.6 Da ( Figure 1A , panel a). This result was unexpected since the protein is known to run from 14 to 16KDa by PAGE analysis. The PSP94 used in the present study was detected as a single band of 16 KDa by PAGE and Western blot analyses (data not shown), which is in agreement with a previous report. 16 Furthermore, the mass determined by SELDI agrees with previously published MS results, which suggests there are three related PSP species belonging to a family of immunoglobulin binding proteins. 18 PAP has a predominant peak at 47226.8 Da ( Figure  1A , panel b), which is in close agreement with a mass of 45 ± 50 KDa determined by PAGE. 12, 19 PSMA has been determined to have a molecular mass of approximately 100 KDa by PAGE and Western blot analyses. 14 By SELDI analysis there is a peak at 100,450 Da, a doubly charged species of 50314.5 Da, and a contaminant or breakdown product at 48160.6 Da ( Figure 1A , panel c). The mass spectra of puri®ed EVMS-PSA, prepared in our laboratory, and three commercial sources of puri®ed PSA bound to hydrophobic H1 chips are shown in Figure This peak is also present in the sample from Bio-Design. Overall the EVMS-PSA appeared to be the most pure based on the number of contaminants detected by this analysis.
The protein detection response by laser desorption/ ionization mass spectrometry depends heavily on the ability of a particular protein to`¯y' from a solid phase when mixed with an acidic EAM. Different intensities can result, as shown in Figure 1 , based on various factors. Acidic and hydrophobic proteins have less tendency to desorb and ionize well, hence less intensity is detected even when these proteins are present in equivalent quantities. Higher mass proteins, such as PSMA, because of the broadening effect of the peak, will also have lower peak intensities. Proteins with post-translational modi®cations such as glycosylation and phosphorylation will also have lower detectable peak intensities because of micro-hetrogeneity within that protein. The amount of protein and amount of EAM can also affect the peak intensity. However, within a given sample, the ratio of peaks remains constant. For a particular protein there is a linear concentration ± intensity relationship for at least two orders of magnitude. For small peptides and proteins, the detection range is linear from pg/ml to ng/ml, and for larger proteins, the detection range is linear from ng to mg/ml.
LCM samples
Approximately 2000 normal prostate (NP) and prostate cancer (PCA) epithelial cells were procured by laser capture microdissection (LCM) from the same surgical tissue section. Representative examples of laser capture microdissected (LCM) procured cells are shown in Figure  2 . Cell lysates of the LCM procured cells were prepared and analyzed by SELDI. Examples of the mass spectra of the proteins present in lysates derived from LCM NP and PCA epithelial cells from the same tissue specimen, using hydrophobic H4 chip arrays, are shown in Figure 3 . Peaks similar to the molecular weights of pure free-PSA, PAP, PSMA and PSP were observed. PSA and PAP were shows the spectrum of PSA purchased from Biodesign. A peak at 28,235.6 Da and a doubly charged species at 14,150.5 Da was observed, along with three unidenti®ed peaks with approximate masses of 5500, 11,000 and 18,000 Da. Panel (b) shows the spectrum of PSA purchased from Medix. A peak at 28,175.4 Da, a doubly charged species at 14,038.2 Da, and a major contaminant at 6000 Da were detected. Panel (c) shows the spectrum of PSA purchased from Sigma. A peak at 28,182.3 Da, a doubly charged species at 14,141.7 Da, and unidenti®ed peaks at 6000 and 11,000 Da were observed. Panel (d) shows the spectrum of the PSA-EVMS prepared in our laboratory. A peak at 28,432.2 Da, a doubly charged species at 14,272.5 Da, and a peak at 18,000 Da were observed.
detected in both specimens, but PSMA was only detected in the lysates of microdissected PCA cells ( Figure 3A) . Analysis of other matched normal and cancer samples, con®rmed the upregulation of PSMA in the cancer cell lysates (data not shown). A presently unidenti®ed protein (arrow) at 33,436 Da also appeared to be upregulated in the prostate adenocarcinoma LCM samples when compared to the mass spectra of the matched normal cell lystate. The upregulation of this protein was found in all six PCA samples tested when compared to the spectra of matched normal cell lysates (data not shown). None of these proteins were detected in lysates of prostate stroma. Figure 3B shows the detection of a protein (10,736.7 Da) similar to the mass of one of the PSP isoforms in a cell lysate of LCM-procured normal prostate epithelial cells. PSP of a similar mass was also detected in the PCA cell lysates (data not shown).
Besides the 33,436 Da protein, the analysis of normal and cancer matched LCM specimens revealed additional protein species that also appear to be upregulated in the PCA samples. Examples of potential candidate PCA biomarkers are shown in Figure 4A and B. Figure 4A is the trace and gel view of three matched samples. A protein (arrow) with a mass of 17,970.8 Da was found to be upregulated in all three PCA samples. Several small mass proteins (between 1 and 10 KDa) were also identi®ed in the cancer cell lysates but not in the normal cell lysates. An example of a protein with a mass of 3573.9 Da was shown to be upregulated in the three PCA samples ( Figure 4B ). These proteins were not detected in stroma lysates (data not shown).
Body¯uids
Seminal plasma and serum from normal and PCA patients were analyzed to determine if the prostate biomarkers PSP, PSA, PAP and PSMA could also be detected in these body¯uids by direct binding to chemical surfaces. Representative spectra of the proteins bound to normal phase NP1 chip arrays are shown in Figure 5A and B. Proteins similar to the molecular weights of PSP, free PSA, and PSMA were identi®ed in serum ( Figure 5A ). These three biomarkers plus a peak with a mass similar to PAP were identi®ed in SP ( Figure 5B) . To test the reproducibility in detecting these proteins in body¯uids, intra-and inter-assay reproducibility experiments were performed. Figure 5C shows that both the intra-and inter-assay variability was quite acceptable. The intra-assay was performed in quadruplicate, and the inter-assay analysis was performed on three different days. The spectra within and between assays show good reproducibility. The mean mass, SD and CV was determined for three of the more prominent proteins designated protein 1 (free-PSA?), protein 2 (PAP?), and protein 3 (albumin? 33 Da (0.04%), 67,243.4 AE 37 Da (0.05%), and the interassay value was 67,296.508 AE 60 Da (0.09%).
The spectra of both serum and SP ( Figure 5A and B) also showed a prominent peak with mass of 79,664.1 Da (serum) and 81,407.6 Da (SP). We suspected that this might possibly be the complexed form of PSA bound by ACT. To test this hypothesis, puri®ed free PSA and PSA ACT (Biodesign) were tested by direct binding onto a normal phase ProteinChip 1 array. As shown in Figure 6 , free-PSA has a peak at a mass of 28,201 Da, ( Figure 5A ) and a dimer peak of 56,248.2 Da. The complexed PSA had a peak at 81,855.2 Da, a doubly charged peak at 41,262.8 Da, and a small amount of contamination free-PSA (28,520.5Da) ( Figure 6B ). This mass is very close to the predicted mass for PSA-ACT of between 78 and 82 KDa. 20 
SELDI immunoassay
Although peaks with masses that corresponded to the four PCA biomarkers were readily detected, we could not rule out that the peaks could be some other protein with a similar mass. For example, the 79 ± 81 KDa peak identi®ed in serum and SP ( Figure 5 A and B) considered to represent PSA-ACT, could be transferrin which has a calculated mass of 77,049 Da (Swiss-Pro Database) and Figure 4 Representative examples of the identi®cation of potential prostate cancer biomarkers in cell lysates by SELDI analysis of proteins bound to hydrophobic H4 ProteinChip 1 arrays. (A) A peak of approximately 18,000 Da (arrows) was identi®ed to be upregulated in the gel view of all three PCA lysates when compared to the three normal prostate epithelial cell lysates. The raw spectrum (top) corresponds to the PCA no. 1 lysate. (B) A peak of 3574 Da (arrow) was found to be upregulated in the PCA samples when compared with the normal prostate cell lystates tested. The raw spectrum (top) corresponds to the PCA no. 1 lysate.
the 28,423.9 Da peak identi®ed in serum ( Figure 5A ) may not be free PSA but could be apolipoprotein A-I, which has a calculated mass of 28,079 Da (Swiss-Pro Database). For these reasons, a SELDI immunoassay was developed to assess the versatility of the ProteinChip 1 SELDI system to speci®cally bind and identify biomarkers in body¯uids using antibody bound chips in place of direct binding to nonselected chemical surfaces.
Initial experiments were conducted to determine if a linear standard curve could be obtained. Figure 7A shows the superimposed spectral traces obtained using 0 ± 50 ng/ml of pure EVMS-PSA antigen. By plotting PSA peak area vs protein concentration, a linear standard curve could be obtained ( Figure 7B ). At 100 ng/ml PSA a saturation point was reached as the curve was no longer linear. Reproducible linear standard curves could also be achieved with low concentrations of PSA (ie, 1 ± 12 ng/ml) (data not shown). Although linear standard curves could be generated for all the biomarkers, the level of saturation varied considerably. For example, the level of saturation for PSP was at 10 ng/ml; therefore a linear progression is obtained only up to 8 ng/ml ( Figure 7C ).
The SELDI immunoassay was used to capture and detect the prostate cancer-associated biomarkers in serum and SP by either binding single or two different antibodies to pre-activated chips. Figure 8 is a representative example of the detection of free PSA, PSP, and PSMA in SP. Peaks with masses corresponding to PSP (10,615 Da), and free-PSA (28,067.6 Da) were detected using the relevant antibody alone ( Figure 8A , panels a and b). Both PSP and free-PSA could also be readily detected using a multiplex SELDI where both antibodies were bound to the same chip array ( Figure 8A, panel c) .
Similarly free PSA and PSMA could be simultaneously Representative experiment showing intra-assay and inter-assay reproducibility of SP spectra. Intra-assay analysis was performed in quadruplicate, and the inter-assay analysis was performed on three different days. For the intra-assay analysis, the mean AE s.d. of the mass for three proteins (identi®ed as protein 1, protein 2 and protein 3) is indicated. Normal phase NP1 chips were used to generate the spectra shown in Figure 5A and B, and hydrophobic H4 chip arrays were used for the reproducibility experiments shown in Figure 5C .
detected with a multiplex SELDI immunoassay ( Figure  8B , panel c). There is a slight decrease in the peak size for each antigen captured when two antibodies of equal concentration are bound to the same chip array. This is probably due to a decrease in available binding sites for each antibody. PSP, free PSA, and PSMA were not detected when an isotype-matched immunoglobulin was substituted for the relevant antibodies ( Figure 8A,  panel d, B, panel d) .
Since PSP has a low mass it`¯ies' off with greater intensity, such that PSA is observed as a broad peak when the intensity is set for maximizing the detection of PSP using the multiplex format ( Figure 8A ). If the intensity was maximized for PSA, then PSP would be off the scale. Sharpening the PSA peak can be accomplished by using the intensity that optimizes the resolution of PSA and adjusting the mass axis ( Figure 8A' ). This was also true for enhancing the resolution of PSMA (Figure 8B' ). PSA and PSMA, because they are glycoproteins with micro-heterogeneity in the carbohydrate composition not resolved by the mass spectrometer, will tend to have broader peaks than non-glycoproteins.
To speci®cally detect PSA-ACT in body¯uids, SELDI immunoassays were ®rst constructed to evaluate antibodies speci®c for just the free PSA, PSA-ACT, or both. Figure 9A shows spectra obtained when the three antibodies or the isotype-matched control antibody was reacted with pure free-PSA. Free PSA was bound only by the MoAb to free-PSA or the MoAb to total PSA ( Figure 9A, panels a,c) . When the antibodies were reacted to complexed PSA, only MoAb to PSA-ACT and total PSA resulted in the detection of PSA-ACT with a mean mass of 81,610.3 Da (Figure 9 B, panels b and c) . The identi®cation of a mass of 81,449.5 ± 81,771.1 Da corresponds to the mass of pure complexed PSA (81,855.9 Da) previously determined on a nonselective chemical surface ( Figure  6 ). Free PSA was also bound by these two antibodies but to a lesser extent. This was to be expected since the pure PSA-ACT (Biodesign) was contaminated with a small amount of free PSA ( Figure 6 ). The near absence of either a 28 or a 81 KDa protein peak in the isotype matched immunoglobulin control spectra ( Figure 9A and B, panel d) validates the speci®city of the assay for the identi®cation of both the free and complexed forms of PSA. By using MoAb to total PSA, the correct masses for both free and complexed PSA could be detected in SP and serum ( Figure 9C, panels a and b) , but not when the control IgG was used ( Figure 9C, panel c) . Both forms of PSA could also be detected when different MoAbs to free PSA and to PSA-ACT were bound to a single PS1 chip array, but with some loss in intensity of the two PSA species (data not shown).
Discussion
The results of this study demonstrate the sensitivity and versatility of the protein biochip based SELDI-TOF-MS for the rapid and simultaneous resolution and identi®ca-tion of multiple cancer biomarkers in complex protein mixtures. The direct SELDI analysis of the selected prostate cancer biomarker proteins bound to chemically de®ned protein chips was found to be highly reproducible, with low background. Experiments, including data acquisition and computer software analyses, were usually completed within a few hours. Masses similar to the masses obtained when the pure biomarkers, ie free PSA, PAP, PSP and PSMA were analyzed could readily be identi®ed in cell lysates, serum and seminal plasma. PSMA, which is 100 KDa and highly glycosylated (15 ± 20%) membrane glycoprotein, required slightly higher laser energy to resolve. Although we did not attempt to quantitate the proteins, this is likely possible by the inclusion of a standard protein with known mass and concentration, or by normalizing to some internal protein.
The linkage of SELDI with the laser capture microdissection microscope has permitted the resolution of proteins from small numbers of procured cells, less than 2000 epithelial cells. This offers tremendous opportunities to discover and identify the signature proteins associated with a particular cell type, making it potentially possible to identify the ®ngerprint protein pro®les for each stage of tumor development. In this study, both known prostate cancer-associated biomarkers, ie PSA, PAP, PSP and PSMA, and unidenti®ed proteins clearly associated with PCA, were readily detected by SELDI analysis of LCM procured cell lysates. The ®nding that PSMA was upregulated in PCA cells agreed with early reports from our laboratory using immunohistochemistry to evaluate the differential expression of this prostate cancer-associated membrane glycoprotein. 21, 22 Although our primary purpose of this study was to determine the effectiveness of the SELDI to resolve the four prostate cancer biomarkers, the identi®cation of other proteins, such as the 33, 18 and 3.5 KDa proteins found unique or upregulated in PCA cells, was an important observation. These unidenti®ed proteins may represent known or possibly novel protein biomarkers, and strongly suggests that the SELDI system will have considerable potential for the discovery of unique prostate cancer biomarkers and protein alterations associated with neoplasia. This observation is supported by a recent preliminary report 23 that described the ®nding of highly reproducible protein ®ngerprints of cancer cells compared to normal and pre-cancerous cells by SELDI. Like our study, only a small number of specimens (n 3) were evaluated, therefore additional studies to evaluate a larger number of samples will be required to determine the signi®cance of these initial observations. Nonetheless, the ability to rapidly and reproducibly evaluate the protein content of pure populations of each cell type in a tissue specimen by micro techniques is in itself a major achievement. Of special interest was the resolution of a number of protein peaks under 10,000 Da, some of which appear to be novel PCA biomarker candidates. The ability of SELDI to rapidly and reproducibly resolve proteins/ peptides under 10 KDa is a distinct advantage over 2D-PAGE.
No attempt was made to achieve maximal resolution of the proteins in cell lysates, serum, and semen since it was possible to obtain masses similar to the four known prostate biomarkers using either the hydrophobic H4 or normal phase (NP1) chip chemistries. These surfaces have been shown to bind a large number of proteins, and was determined to be a good starting point to evaluate the SELDI system. However, if maximal resolution is desired it may be necessary to use a combination of chip chemistries, EAMs, and washing stringencies. For example, Ciphergen scientists have recently been able to resolve over 300 proteins in serum by passing the serum through a Cibacron Blue spin column to reduce the albumin concentration, and then using four different surface chemistries (Yip et al, unpublished observations) . A fractionation step prior to SELDI analysis of serum may be essential to resolve low abundance proteins masked by albumin and immunoglobulins, which make up 80% of the protein concentration of sera. Also with LCM microdissected procured cells it will be essential to maximize the extraction of proteins from the LCM cap surface while minimizing protein dissociation and denaturation. Although resolution of proteins from as few as 20 ± 30 LCM cells is possible, maximal resolution of proteins in the cell lysates, especially high MW proteins and proteins in low abundance, may require larger numbers of cells. Using cell lysates from 2000 LCM procured cells, we were able to resolve proteins with molecular weights greater than 100 KDa. As a result, the number of cells required to achieve maximal protein resolution by SELDI is orders of magnitude less than the 50,000 or more LCM procured cells found to be required for 2D-PAGE. 24, 25 Although masses similar to the molecular weights of the four known PCA biomarkers could be detected in spectra of all complex biological mixtures tested using nonselective chemical ProteinChip 1 arrays, there was no way to be certain that the mass actually was the PCA biomarker or some other protein with a similar mass. With some proteins, the mass values were within a tolerable 1% variance, whereas others were as much as 3% variance from the masses obtained when the pure standards were analyzed. This variance may have resulted from a mass shift caused by salt aducts, bound ligands, other proteins or binding peptides present in the native complex protein mixture, and differences in posttranslational modi®cations. Two approaches to resolve this issue could be used: To purify the protein, perform peptide mapping, and then identify the protein by comparing the tryptic maps with a protein database; or identify the proteins with immunoassays. We chose the latter since the SELDI platform was readily adaptable for developing an immunoassay format. This approach, using antibodies as the af®nity capture device, has been successfully used to detect and quantitate antigens by MS in complex biological mixtures. 10, 26 Unlike current ELISA technology, which uses an indirect detection mechanism by`sandwiching' the target protein with antibodies, SELDI-based immunoaf®nity assays allow for direct, sub-femtomole detection without tags. Additionally, multiple binding events, ie macromolecular complexes etc, can readily be detected and analyzed. The detection of both free PSA (28 KDa) and PSA complexed with alpha1-antichymotrypsin (PSA-ACT) (81 KDa) in both serum and SP is a good example of the latter. The identi®cation PSA-ACT with a mass of 81 KDa agrees with a recent publication which described the ®nding of two predominant protein species in PSA-ACT preparations by mass spectrometry, at 79,095 AE 138 and 82,519 AE 104 Da. 20 Interestingly, they also identi®ed multiple species of ACT, with the two predominate species having masses of 55,106 AE 111 and 51,414 AE 132 Da, whereas free PSA contained a single molecular mass of 27,755.8 Da, which is in agreement with our observations. Although we did not determine the mass for the ACT used to generate the PSA-ACT used in our study, the identi®cation of an 81 KDa is in agreement with the latter and other published studies, 20, 27 where the molecular mass was found to range , when using the multiplex assay, could be enhanced by selecting the optimal intensity for either PSA (A') or PSMA (B') and adjusting the mass axis.
from 80 and 98 KDa. The variation in molecular masses for PSA-ACT, therefore, may be due to the differences in the ACT raw material used to prepare the PSA-ACT complex. Most relevantly, our data of capturing an 81,743 Da PSA-ACT complex from both SP and serum using speci®c antibodies unequivocally identi®es the complex molecular mass in the native biological state.
Besides PSA (free and complexed), we were also successful in developing SELDI immunoassays for speci®-cally detecting PSMA and PSP in the cell lysates and body¯u ids. The identi®cation of three distinct species of PSP by direct binding to chip arrays was unexpected because only a single 16 KDa band was observed on Western blots. 16 However, a search of the literature supports the observation that PSP may exist in three different isoforms. Three protein spots, each with a molecular weight of 15,000 Da but with differing isoelectric points ranging from pI 5.6 to 6.6, were detected in prostatic¯uid by 2D-PAGE. 19 More recently, three components having immunoglobulin binding factor (IgBF) activity were isolated by HPLC with masses of 10,769, 10,644 and 11,253 Da determined by MS. 20 The protein with the mass of 10,769 Da was identi®ed to be the main IgBF species while the 10,644 Da and the 11,253 Da protein species were identi®ed as the PSP and prepeak IgBF, respectively. Based on gene and structural analyses, these investigators concluded that PSP is a member of the immunoglobulin binding factor family. The identi®ca-tion of a major peak at 10.6 KDa in SP by the SELDI immunoassay is in agreement with the mass (10,644 Da) they determined to be PSP.
Of considerable interest was the successful development of multiplex SELDI immunoassays, where two different antibodies bound on single chip array, to simultaneously capture the corresponding antigens from bodȳ uids. The limits to how many different antibodies can be docked on a single chip and how this affects the sensitivity and quantitation of the antigens remain to be determined. Nevertheless, this approach has considerable potential for measuring a large number of different proteins on a single eight or 12 array chip, either in a single or multiplex format. The only potential dif®culty with the SELDI immunoassay used in this study could be the masking of the speci®c antigen by the ionization and binding of dissociated intact Ig, light and heavy Ig chains, small amounts of protein G and albumin, and the generation of double charged Ig adducts. This, however, was not a problem in the detection of free PSA, PSA-ACT, PSP and PSMA. To circumvent the problem of these`nonspeci®c' proteins from interfering with both the detection and quantitation of the antigen, it may be necessary to covalently bind the antibody immunoglobulin directly to the chip. The speci®city of the SELDI immunoassay is unsurpassed even with single antibody assay, because there is the combined discriminating power of both the antibody and the high molecular weight accuracy of the detector. In terms of sensitivity, the detection limit of small peptides and proteins can approach that of ELISA and current clinical assays for PSA. However, for larger proteins, the sensitivity may be less than that of ELISA. No attempt was made in the present study to maximize the sensitivity of the SELDI immunoassays or to quantitate the antigen present in serum and SP. Such studies are in progress. The ability, however, to simultaneous identify free PSA and PSA-ACT by SELDI immunoassays, as demonstrated in this study, offers an entirely novel approach for the detection and quantitation of free PSA, complexed PSA (PSA-ACT), and total PSA in body¯uids. At present two or three separate immunoassays are required to measure these three PSA forms in serum.
Conclusions
This study has shown that discovery, protein identi®ca-tion and development of a clinical assay are all potentially possible with SELDI using the same chip platform. The SELDI system is a rapid, highly reproducible, cost effective system for the simultaneous resolution of multiple prostate cancer-associated biomarkers. Unlike¯uores-cence detection methods and other`indirect' molecular detection strategies, proteins are detected directly by the SELDI process. Direct detection all but eliminates`false positives' that detract from other marker protein assays and greatly decreases assay variability associated with multiple step ampli®cation and labeling processes. Furthermore, compared to alternative protein discovery and mapping approaches, such as two dimensional gel electrophoresis, the SELDI approach requires less time and expertise, has greater sensitivity for trace proteins (`fmol/ml using chemical arrays), dynamic range, and feature' resolution for protein analysis. Thus, the SELDI system offers a signi®cant advancement in the use of mass spectrometry for the analysis of proteins, and promises to have a major impact on the proteomic ®eld from discovery, identi®cation, analysis of post-translation modi®cations of disease-associated proteins, to development of clinical assays for their detection and assessment in complex biological¯uids. Our goal is to use this novel protein biochip SELDI technology and trace protein detection strategy to identify the signature ®ngerprint protein pro®les unique for prostate cancer, and then use these pro®les to develop a rapid high throughput clinical assay for the diagnosis/prognosis of prostate cancer.
